Theralase Technologies Inc. (TLT) - Net Assets

Latest as of March 2026: CA$1.95 Million CAD ≈ $1.41 Million USD

Based on the latest financial reports, Theralase Technologies Inc. (TLT) has net assets worth CA$1.95 Million CAD (≈ $1.41 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$3.89 Million ≈ $2.81 Million USD) and total liabilities (CA$1.94 Million ≈ $1.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TLT intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CA$1.95 Million
% of Total Assets 50.12%
Annual Growth Rate 11.27%
5-Year Change -64.94%
10-Year Change -68.76%
Growth Volatility 279.17

Theralase Technologies Inc. - Net Assets Trend (2001–2025)

This chart illustrates how Theralase Technologies Inc.'s net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Theralase Technologies Inc. to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Theralase Technologies Inc. (2001–2025)

The table below shows the annual net assets of Theralase Technologies Inc. from 2001 to 2025. For live valuation and market cap data, see market value of Theralase Technologies Inc..

Year Net Assets Change
2025-12-31 CA$1.78 Million
≈ $1.29 Million		 -14.01%
2024-12-31 CA$2.07 Million
≈ $1.50 Million		 +8.50%
2023-12-31 CA$1.91 Million
≈ $1.38 Million		 -38.39%
2022-12-31 CA$3.09 Million
≈ $2.24 Million		 -39.00%
2021-12-31 CA$5.07 Million
≈ $3.67 Million		 -44.67%
2020-12-31 CA$9.16 Million
≈ $6.63 Million		 -33.86%
2019-12-31 CA$13.86 Million
≈ $10.02 Million		 +1287.43%
2018-12-31 CA$998.64K
≈ $722.40K		 -51.18%
2017-12-31 CA$2.05 Million
≈ $1.48 Million		 -64.06%
2016-12-31 CA$5.69 Million
≈ $4.12 Million		 -9.90%
2015-12-31 CA$6.32 Million
≈ $4.57 Million		 +91.10%
2014-12-31 CA$3.31 Million
≈ $2.39 Million		 +87.39%
2013-12-31 CA$1.76 Million
≈ $1.28 Million		 +2824.99%
2012-12-31 CA$-64.73K
≈ $-46.82K		 -114.22%
2011-12-31 CA$455.16K
≈ $329.25K		 -82.01%
2010-12-31 CA$2.53 Million
≈ $1.83 Million		 -27.43%
2009-12-31 CA$3.49 Million
≈ $2.52 Million		 +46.10%
2008-12-31 CA$2.39 Million
≈ $1.73 Million		 -29.22%
2007-12-31 CA$3.37 Million
≈ $2.44 Million		 +0.03%
2006-12-31 CA$3.37 Million
≈ $2.44 Million		 -0.57%
2005-12-31 CA$3.39 Million
≈ $2.45 Million		 +221.81%
2004-12-31 CA$1.05 Million
≈ $762.12K		 +163.91%
2003-12-31 CA$399.21K
≈ $288.78K		 +357.03%
2002-12-31 CA$87.35K
≈ $63.19K		 -36.26%
2001-12-31 CA$137.03K
≈ $99.13K		 --

Equity Component Analysis

This analysis shows how different components contribute to Theralase Technologies Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 6690240600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components CA$73.39 Million 4128.37%
Total Equity CA$1.78 Million 100.00%

Theralase Technologies Inc. Competitors by Market Cap

The table below lists competitors of Theralase Technologies Inc. ranked by their market capitalization.

Company Market Cap
Prinsiri Public Company Limited
BK:PRIN
 $51.34 Million
Selangor Dredging Bhd
KLSE:2224
 $51.35 Million
DDC Enterprise Limited
NYSE MKT:DDC
 $51.36 Million
flyExclusive, Inc.
NYSE:FLYX
 $51.37 Million
Oneflow AB
ST:ONEF
 $51.33 Million
Prestige Wealth Inc.
NASDAQ:AURE
 $51.29 Million
Shenzhen SEG Co Ltd
SHE:200058
 $51.28 Million
Instil Bio Inc.
NASDAQ:TIL
 $51.27 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Theralase Technologies Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,067,448 to 1,777,816, a change of -289,632 (-14.0%).
  • Net loss of 4,120,817 reduced equity.
  • New share issuances of 2,976,099 increased equity.
  • Other factors increased equity by 855,086.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CA$-4.12 Million -231.79%
Share Issuances CA$2.98 Million +167.4%
Other Changes CA$855.09K +48.1%
Total Change CA$- -14.01%

Book Value vs Market Value Analysis

This analysis compares Theralase Technologies Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 35.76x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 36.18x to 35.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CA$0.01 CA$0.24 x
2002-12-31 CA$0.00 CA$0.24 x
2003-12-31 CA$0.02 CA$0.24 x
2004-12-31 CA$0.04 CA$0.24 x
2005-12-31 CA$0.10 CA$0.24 x
2006-12-31 CA$0.10 CA$0.24 x
2007-12-31 CA$0.10 CA$0.24 x
2008-12-31 CA$0.07 CA$0.24 x
2009-12-31 CA$0.10 CA$0.24 x
2010-12-31 CA$0.06 CA$0.24 x
2011-12-31 CA$0.01 CA$0.24 x
2012-12-31 CA$0.00 CA$0.24 x
2013-12-31 CA$0.04 CA$0.24 x
2014-12-31 CA$0.04 CA$0.24 x
2015-12-31 CA$0.07 CA$0.24 x
2016-12-31 CA$0.05 CA$0.24 x
2017-12-31 CA$0.02 CA$0.24 x
2018-12-31 CA$0.01 CA$0.24 x
2019-12-31 CA$0.10 CA$0.24 x
2020-12-31 CA$0.04 CA$0.24 x
2021-12-31 CA$0.02 CA$0.24 x
2022-12-31 CA$0.01 CA$0.24 x
2023-12-31 CA$0.01 CA$0.24 x
2024-12-31 CA$0.01 CA$0.24 x
2025-12-31 CA$0.01 CA$0.24 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Theralase Technologies Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -231.79%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -504.71%
  • • Asset Turnover: 0.23x
  • • Equity Multiplier: 1.97x
  • Recent ROE (-231.79%) is below the historical average (-105.94%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -127.76% 0.00% 0.00x 1.07x CA$-188.78K
2002 -56.88% -2091.92% 0.02x 1.12x CA$-58.42K
2003 -12.44% -179.11% 0.05x 1.54x CA$-89.57K
2004 5.63% 9.03% 0.54x 1.15x CA$-46.01K
2005 0.38% 1.07% 0.34x 1.05x CA$-326.15K
2006 -8.37% -19.62% 0.39x 1.09x CA$-619.10K
2007 -33.02% -71.38% 0.42x 1.10x CA$-1.45 Million
2008 -46.58% -51.27% 0.68x 1.33x CA$-1.35 Million
2009 -6.93% -10.24% 0.56x 1.20x CA$-590.27K
2010 -47.41% -58.79% 0.63x 1.28x CA$-1.45 Million
2011 -319.44% -71.73% 1.44x 3.10x CA$-1.50 Million
2012 0.00% -82.75% 1.61x 0.00x CA$-1.50 Million
2013 -65.32% -95.73% 0.45x 1.52x CA$-1.33 Million
2014 -78.28% -187.42% 0.36x 1.15x CA$-2.92 Million
2015 -82.45% -267.74% 0.27x 1.12x CA$-5.84 Million
2016 -86.47% -256.46% 0.31x 1.10x CA$-5.49 Million
2017 -297.89% -260.13% 0.70x 1.62x CA$-6.30 Million
2018 -336.15% -193.58% 0.49x 3.57x CA$-3.46 Million
2019 -53.60% -770.32% 0.06x 1.12x CA$-8.81 Million
2020 -61.20% -603.60% 0.09x 1.09x CA$-6.52 Million
2021 -87.11% -565.74% 0.13x 1.17x CA$-4.92 Million
2022 -169.71% -460.97% 0.27x 1.35x CA$-5.56 Million
2023 -239.89% -427.06% 0.33x 1.72x CA$-4.76 Million
2024 -205.86% -411.84% 0.32x 1.57x CA$-4.46 Million
2025 -231.79% -504.71% 0.23x 1.97x CA$-4.30 Million

Industry Comparison

This section compares Theralase Technologies Inc.'s net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $4,027,096
  • Average return on equity (ROE) among peers: -59.96%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Theralase Technologies Inc. (TLT) CA$1.95 Million -127.76% 1.00x $51.33 Million
Aurora Spine Corp (ASG) $3.81 Million -19.18% 1.73x $11.58 Million
MedX Health Corp (MDX) $-1.83 Million 0.00% 0.00x $11.86 Million
NuGen Medical Devices Inc (NGMD) $-2.26 Million 0.00% 0.00x $3.28 Million
Perimeter Medical Imaging AI Inc (PINK) $10.76 Million -74.39% 0.22x $27.98 Million
Profound Medical Corp (PRN) $14.29 Million -108.19% 1.09x $245.21 Million
Therma Bright Inc (THRM) $2.75 Million -214.08% 0.46x $2.10 Million
VentriPoint Diagnostics Ltd (VPT) $670.44K -3.91% 0.01x $16.29 Million

About Theralase Technologies Inc.

V:TLT Canada Medical Devices
Market Cap
$51.33 Million
CA$70.96 Million CAD
Market Cap Rank
#21865 Global
#770 in Canada
Share Price
CA$0.24
Change (1 day)
+0.00%
52-Week Range
CA$0.15 - CA$0.39
All Time High
CA$0.58
Categories
Companies in Canada Medical Devices
About

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more